Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Global X CleanTech (CTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Global X CleanTech — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Global X CleanTech trades at $58.77. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Global X CleanTech nearer its low. Which is the better fit depends on your goals.
| ACAD | CTEC | |
|---|---|---|
Market Cap | $5.06B | — |
Sector | Health | Sector/Thematic |
52-Week High | $29.41 | $78.11 |
52-Week Low | $20.06 | $41.08 |
Enterprise Value | $4.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
CTEC trades at $58.40, up 2.1% today, with a neutral technical signal overall. Moving averages suggest a bullish trend, while oscillators are neutral. The stock faces resistance near $60 and support at $53. A dividend of $0.07 is scheduled for July 2026. Key financial ratios are currently unavailable.
The outlook hinges on upcoming financial disclosures to assess fundamentals. Near-term price action may test resistance at $60. Risks include lack of recent financial data and market volatility. Investor sentiment appears balanced pending further company updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Global X CleanTech
CTEC invests in companies at the forefront of the clean technology industry. It focuses on disruptive innovations in renewable energy production, energy storage, smart grids, and energy efficiency, with top holdings like Enphase and First Solar.
Read more on CTEC →
